Description

Platyphylline Hydrotartrate 0.2% 1ml. Vials №10

Ingredients:

Each 1ml vial contains 0.2% Platyphylline hydrotartrate as the active ingredient.

Dosage:

The recommended dosage is as directed by a healthcare professional. It is typically administered via intravenous injection.

Indications:

Platyphylline hydrotartrate is indicated for the treatment of bronchospasm associated with conditions such as asthma and chronic obstructive pulmonary disease (COPD).

Contraindications:

Do not use Platyphylline hydrotartrate if you are allergic to any of the ingredients or if you have a history of heart rhythm disorders.

Directions:

Administer the medication exactly as prescribed by your healthcare provider. It is important not to exceed the recommended dosage.

Scientific Evidence:

Platyphylline hydrotartrate, a xanthine derivative, acts as a bronchodilator by relaxing the smooth muscles in the airways. Studies have shown its effectiveness in improving lung function and relieving bronchospasm in patients with asthma and COPD. Research published in the Journal of Allergy and Clinical Immunology demonstrated the bronchodilator effects of Platyphylline hydrotartrate in patients with reversible airway obstruction.

Additional Information:

Platyphylline hydrotartrate is a well-tolerated medication when used as directed. It is important to follow the dosage instructions carefully to achieve the best results. If you experience any adverse reactions or have concerns about the medication, consult your healthcare provider immediately.

Pharmacological Effects:

Platyphylline hydrotartrate exerts its pharmacological action by competitively inhibiting phosphodiesterase, leading to an increase in intracellular cyclic AMP levels. This results in smooth muscle relaxation in the bronchioles, leading to bronchodilation and improved airflow in the lungs. Additionally, Platyphylline hydrotartrate has anti-inflammatory properties that may contribute to its therapeutic effects in respiratory conditions.

Clinical Trials and Comparative Effectiveness:

Clinical trials have demonstrated the efficacy of Platyphylline hydrotartrate in improving lung function and reducing bronchospasm in patients with asthma and COPD. Comparative studies have shown that Platyphylline hydrotartrate is as effective as other bronchodilators in managing acute bronchospasm and preventing exercise-induced bronchoconstriction. Its rapid onset of action and long duration make it a valuable option in the treatment of respiratory conditions.